---
trial_id: 268
discovery_date: 2022-03-29 21:28:28.071281
date: 2022-03-29 21:28:28.071281
title: "Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohnâ€™s disease"
summary: |
  <p>EudraCT Number: 2006-004784-58<br />Sponsor Protocol Number: MRI-0143<br />Sponsor Name: University of Leuven<br />Start Date: 2007-06-22<br />Medical condition: Crohn's disease<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10011401<br />Term: Crohn's disease<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/BE">BE</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/FR">FR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/GB">GB</a> (Prematurely Ended)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004784-58'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2006-004784-58<br />Sponsor Protocol Number: MRI-0143<br />Sponsor Name: University of Leuven<br />Start Date: 2007-06-22<br />Medical condition: Crohn's disease<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10011401<br />Term: Crohn's disease<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/BE">BE</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/FR">FR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/GB">GB</a> (Prematurely Ended)</p>